



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	HIV-1 pNL4-3.HSA.R-E-
<b>Catalog Number:</b>	3417
<b>Lot Number:</b>	150362
<b>Release Category:</b>	C
<b>Provided:</b>	5 µg of dried purified DNA stabilized in DNASTable <i>Plus</i>
<b>Cloning Vector:</b>	pUC-19. Amp resistant.
<b>Description:</b>	Two frameshifts render this NL4-3 clone Env- and Vpr-. When cotransfected with an Env expression vector it will produce infectious virus that is competent for a single round of infection.
<b>Special Characteristics:</b>	<p>The murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene to produce this clone. Virus can be produced by transfecting <math>2 \times 10^6</math> 293 or 293T cells with 10 µg NL4-3 DNA and 10 µg env expression vector DNA. Transfections can be performed in a 10 cm<sup>2</sup> tissue culture dish using standard calcium phosphate protocols. Virus is typically harvested 48 hours post-transfection. Infections should be performed in a total volume of 0.5 ml. The amphotropic pseudotypes generally have much higher infectivity than those bearing HIV-1 env. Cultures infected with HSA viruses can be assayed by FACS analysis with a commercial CD24 antibody (Pharmingen) 2-5 days post-infection.</p> <p><a href="#">Contributor provided sequence information</a></p> <p>This reagent is currently being provided as dried purified DNA stabilized in DNASTable <i>Plus</i>. Please see the notice for additional information and the protocol for reconstitution of dried DNA reagents. <a href="#">Dried DNA Notice</a></p>
<b>Recommended Storage:</b>	Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.
<b>Contributor:</b>	Dr. Nathaniel Landau.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:**

He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol* **69**:6705-6711, 1995. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. *Virology* **206**:935-944, 1995.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 pNL4-3.HSA.R<sup>-</sup>.E<sup>-</sup> from Dr. Nathaniel Landau." Also include the references cited above in any publications. Patent pending.

**Requests from commercial organizations must be directed to the New York University Office of Industrial Liaison at the following email address: [sadhana.chitale@nyumc.org](mailto:sadhana.chitale@nyumc.org).**

**Last Updated**

June 21, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.